Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Patients in Ontario Can Now Access Trikafta Through Public Plan

People with cystic fibrosis (CF) in Ontario, Canada, will now have access to the triple-combination therapy Trikafta through the province’s publicly funded drug program. “Our government has taken urgent action to ensure all cystic fibrosis patients will have more timely access to the effective and lifechanging treatments they need,”…

Adults With CF Can Connect at BreatheCon

A two-day virtual event called BreatheCon will offer adults with cystic fibrosis (CF) an opportunity to connect and share their experiences through open and honest dialogue. Registration for the Sept. 24–25 event, which is hosted by the Cystic Fibrosis Foundation, is free online. “CF can be extremely…

ELX-02, Potential CF Nonsense Mutation Therapy, on FDA Fast Track

The U.S. Food and Drug Administration (FDA) has given fast track designation to ELX-02, an investigational treatment for people with cystic fibrosis (CF) caused by nonsense mutations. This FDA designation aims to speed the development and regulatory review of potential treatments for serious or life-threatening diseases with an unmet medical…

Relizorb Will Be Covered by Medicare

The Centers for Medicare and Medicaid Services (CMS) has published a local coverage determination confirming that Relizorb — an enzyme cartridge to help in digestion for cystic fibrosis (CF) patients receiving their nutrition through enteral feeding — will be covered by Medicare.

Polyphor and EnBiotix to Merge, Plan Trials in 2 Lung Infection Therapies

EnBiotix has purchased murepavadin, an investigational inhaled antibiotic to treat Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), from Polyphor. The two companies also entered into an agreement to merge, wherein Polyphor will acquire all EnBiotix stock in exchange for Polyphor stock newly issued upon closing. The merger…

Study: Use Lung Clearance Index to Measure Function

An assessment called the lung clearance index could be used to help identify people with cystic fibrosis (CF) who are at high risk for worsening lung function, a study has found. The study reported on factors associated with a worsening lung clearance index (LCI) over time in CF patients,…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.